dostarlimab-gxly

dostarlimab-gxly (JEMPERLI) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

JEMPERLI is a marketed brand name for dostarlimab-gxly. Check FDA Drugs@FDA for the current US label holder and prescribing information.

dostarlimab-gxly has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.